Cancer BiologybioRxiv
Burden of tumor mutations, neoepitopes, and other variants are dubious predictors of cancer immunotherapy response and overall survival
M. A. Wood, B. R. Weeder, J. K. David…·R. F. Thompson
This study evaluates tumor mutational burden (TMB) and related metrics as predictors of immunotherapy response and survival, finding limited predictive value in some cancers and instability in its use.
DOI 10.1186/s13073-020-00729-2